Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2016

View Archived Issues

Efficacy and safety of ribavirin-free DAA treatments in patients with severe renal impairment

AzurRx BioPharma and Mayoly Spindler launch phase II study of MS-1819-SD

EC grants orphan drug designation to Ra Pharmaceuticals' RA-101495

L807-mts demonstrates promising results in mouse model of Alzheimer's disease

Novel Zika virus infection model in immunocompetent neonatal C57Bl/6 mice

VH-298 is a novel potent and selective chemical probe of hypoxic signaling

Novel animal models presented at the Society for Neuroscience annual meeting

Nippon Boehringer Ingelheim and Astellas launch Micatrio combination tablets in Japan

PharmAkea extends collaboration with Celgene

Omeros patents PDE10A inhibitors

University of North Carolina at Chapel Hill discloses anticancer agents

Shanghai Fochon Pharmaceutical describes CDK4/cyclin D1 and CDK6/cyclin D1 inhibitors

Chinese scientists develop Nav1.7 channel blockers

Laboratorios del Dr. Esteve presents dual sigma1 and mu-opioid receptor ligands

UMC launches phase II program combining DCVax-L and pembrolizumab

Alzheimer's Association grant supports Proclara's development of NPT-088

Athenex to conduct phase Ib study of Oraxol in combination with ramucirumab

Apricus plans for Vitaros NDA resubmission next year

Medicure to acquire majority interest in Apicore

Novartis acquires Selexys Pharmaceuticals

Aska Pharmaceutical ready to launch Rifxima tablets in Japan

European Commission approves Trisenox for first-line treatment of low to intermediate risk APL

Boehringer Ingelheim launches idarucizumab as reversal agent for dabigatran in Japan

GSK submits NDA for closed triple combination therapy for COPD

Bristol-Myers Squibb launches elotuzumab in Japan

MSD K.K. launches elbasvir and grazoprevir in Japan

Bilanoa launched in Japan

Otsuka launches Iclusig in Japan

Laboratoris Sanifit reports clinical data on SNF-472

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...